May company physicians/researchers address research about the side effects of an off-label use of a company product at a medical conference that qualifies as "independent"? What if the question about the side effects arises in Q&A at the conclusion of a presentation about a company product - how does the FDA classify this "request" and how does the Unsolicited Requests Guidance indicate that it should be handled?